Acute urinary tract infection is a major health problem among women, accounting for considerable morbidity and health care costs. We review recent developments in the diagnosis and treatment of these infections. In acute lower urinary tract infection, empiric short-course therapy (singledose or 3-day therapy) with one of several antibiotics is recommended in the absence of complicating factors. When complicating factors are present, the antibiotic susceptibility profile of the infecting organism should be determined and therapy with an appropriate agent should be provided for 7 days. Ampicillin and related drugs are probably inferior to trimethopHm-sulfamethoxazole in the treatment of occult renal infection. In acute pyelonephritis, most patients require hospitalization and treatment with intravenous antibiotics until they can take oral medications. In uncomplicated cases, a single broad-spectrum intravenous agent can be used initially, followed by an oral agent selected on the basis of antibiotic-susceptibility testing results. Patients with uncomplicated acute pyelonephritis who are less ill can be managed with oral therapy as outpatients, again with reference to the results of antibiotic-susceptibility testing. Complicated acute pyelonephritis requires more aggressive diagnostic and therapeutic measures. Therapy for uncomplicated acute pyelonephritis should be given for 14 days. The role of post-therapy cultures in the management of urinary tract infection is not well defined, but cultures probably can be safely omitted in most cases of uncomplicated acute cystitis. Medicine. 1989;lll:906-917. 
Acute infection of the urinary tract is a common problem, affecting an estimated 10% to 20% of women at some point during their lifetime (1) , and accounting for 5.2 million visits to physicians' offices annually in the United States (2) . Using the traditional approach to diagnosis and treatment, management of an episode of acute cystitis costs an estimated $140 (3); thus, the yearly national health care costs due to uncomplicated lower urinary tract infections in ambulatory patients alone may approach one billion dollars. In addition, more than 100 000 patients are hospitalized annually in the United States for an average of 6 to 7 days because of renal infection (4). In addition to their cost, urinary tract infections cause considerable discomfort and inconvenience to the patient and are occasionally responsible for protracted symptoms or more serious manifestations, such as gram-negative sepsis and death (5).
Acute urinary tract infection is thus a significant health problem. We discuss a practical approach to the treatment of community-acquired urinary tract infections in women, which is designed to minimize cost and adverse effects wbile maintaining therapeutic efficacy.
Clinical Syndromes Associated with Acute Infections of the Urinary Tract
Tbe term "urinary tract infection" includes various quite diiferent clinical syndromes, each with its own unique epidemiology, diagnostic considerations, requirements for therapy, and prognosis. Optimal therapy of urinary tract infection depends on accurate delineation of the particular clinical syndrome present in a given patient.
Lower urinary tract infection, usually termed acute cystitis, results from superficial bacterial infection of the bladder or the urethra, or both. Escherichia coli, otber Enterobacteriaciae, Staphylococcus saprophyticus, or Enterococcus account for over 90% of cases of acute lower urinary tract infection in the noncompromised host (6). Dysuria is the cardinal symptom of lower urinary tract infection. Other symptoms may include urinary frequency, nocturia, urgency, voiding of small volumes, incontinence, and suprapubic or pelvic pain. Suprapubic tenderness is present in only about 10% of patients with cystitis but is a specific finding for cystitis (7).
To manage these patients appropriately, tbe physician must differentiate lower urinary tract infection from otber inflammatory or infectious conditions in which dysuria may be the most prominent symptom.
including vaginitis, urethral infections caused by sexually transmitted pathogens, and miscellaneous noninflammatory causes of urethral discomfort (8, 9) . Attention to characteristic features of the history, of the physical examination, and of voided urine or other specimens allows a patient with dysuria to be assigned to one of these diagnostic categories, as previously reviewed (10).
Approximately one-third of patients who have characteristic symptoms of uncomplicated acute cystitis also have unrecognized infection of the upper urinary tract, as demonstrated through the use of special diagnostic procedures such as bladder washout (11), selective urcteral catheterization (12), or antibody-coated bacteria tests (13, 14) . The percentage of such patients among women presenting with symptoms of lower urinary tract infection has varied from 8% to 80% (15, 16). Difference in the criteria used by various investigators to define a positive antibody-coated bacteria test may contribute to the wide range in the observed prevalence of positive antibody-coated bacteria tests in these studies (15) (16) (17) (18) (19) . In addition, the populations investigated in diflFerent studies may have intrinsically different rates of occult renal infection (15). Various historical features have been associated with an increased likelihood of occult renal infection in a patient with presumed acute cystitis ( Table 1) .
Patients with overt acute upper urinary tract infection classically present with the symptoms of acute pyelonephritis, which include localized flank, low back, or abdominal pain, and systemic symptoms such as fever, rigors, sweats, headache, nausea, vomiting, malaise, and prostration. In patients with acute pyelonephritis, antecedent or concomitant symptoms of cystitis may or may not be present (U). Although the specificity of fever and of flank or loin pain as indicators of renal infection has been debated (12, 20), several studies support the association of these symptoms with upper urinary tract infection (21, 22).
A spectrum of severity of illness is encountered among patients with uncomplicated acute pyelonephritis; some patients have mild symptoms and can continue their usual activities (23), whereas others experience significant pain and debility, and may develop volume contraction from recurrent vomiting that requires intravenous administration of fluids and antimicrobial agents. A few patients with upper urinary tract infection develop complications such as necrotizing intrarenal and perinephric abscesses (24) or overwhelming gram-negative sepsis (5). These severe manifestations occur primarily in compromised hosts (those with urinary tract obstruction, diabetes, or other immunosuppressing conditions) (5, 25, 26) and often necessitate aggressive diagnostic and therapeutic efforts, including emergency ultrasonography or computed tomography and, in some cases, hemodynamic monitoring, prcssor agents, assisted ventilation, or urologic surgery.
Apart from the presumed anatomic site of infection, urinary tract infection syndromes are often assigned to the somewhat ambiguous categories of "complicated" or "uncomplicated" depending on the presence or ab- sence of host conditions known to promote infection, account for persistence of infection, or promote recurrence (25, 27) ( Table 1) . Generally, uncomplicated cystitis or pyelonephritis occurs in young women who lack evidence of structural or functional urologic abnormalities. Essentially all infections in men and infections in women who do have such abnormalities are considered complicated. The distinction between complicated and uncomplicated urinary tract infection is commonly made during the evaluation of new antimicrobial agents (25). It can carry important prognostic implications, because when complicating host factors are present, antimicrobial resistance is commoner (Table 2), response to therapy is often disappointing even with agents active against the patient's pathogen (25), and severe complications of infection frequently occur (25-27). Antimicrobial and adjunctive therapies may require modification in the presence of complicating factors, as we discuss below. In addition, researchers constructing clinical trials in urinary tract infection therapy should identify at the time of patient enrollment the presence of complicating factors. If such patients are to be included, they should be randomized independently and the complicating factors should be described (28). 
Pretherapy Urine Cultures and Rapid Diagnostic Tests
A rigorously defined confirmation of urinary tract infection requires documentation of bacteria in bladder urine, which is normally sterile. In clinical practice, however, the culture is usually done on voided urine, which in women is easily contaminated with perineal bacteria. Quantitative culture and specific identification of the organisms in urine are used to distinguish contamination (usually low count and usually nonpathogenic species) from true bladder infection (usually higher counts of typical uropathogens) (29). The urinary bacterial concentration is determined by culturing a known volume of urine (10-2 or 10-3 mL), or is approximated by using a dip-culture method (10, 30). Thus, in acutely symptomatic women, a tnore appropriate threshold value for defining "significant bacteriuria" is more than 102 colonies/mL of a known uropathogen (31-33). Failure to use this criterion in such patients seriously compromises the sensitivity of the urine culture. Clinicians should encourage their clinical laboratory to adopt techniques which allow detection of 103 cfu/mL and to report cultures with 10^ to 105 cfu/mL as positive. In the interest of cost savings, determination of the species and susceptibility pattern of such "low count" isolates could be omitted unless specifically requested by the referring clinician.
As an alternative to standard overnight culture methods (29, 30), various rapid methods to detect bacteriuria have been recently developed and have been reviewed in detail previously (35). These methods detect bacterial growth using photometry or bioluminescence and can provide results as rapidly as 1 to 2 hours. In general, they achieve a sensitivity of 95% to 98% and a negative predictive value of over 99% compared with conventional cultures when bacteriuria is defined as 10^ cfu/mL or more. Thus, they are excellent for screening out negative cultures using this definition of bacteriuria. Unfortunately, the sensitivity of these tests falls to unsatisfactory levels in detecting bacteriuria between 102 and 10* cfu/mL, which is needed in acutely symptomatic patients.
Although many authorities have recommended that urine culture and antimicrobial-susceptibility testing be done in any patient with a suspected urinary tract infection, in practice this often is not done. Indeed, it may actually be more cost efFective to manage many patients who have symptoms and urinalysis findings characteristic of uncomplicated acute cystitis without an initial urine culture, because treatment decisions are usually made and therapy is often completed before culture results are known (9). In a recent treatment study (36) of urinary tract infection, pretherapy urine cultures were not predictive of the outcome of therapy; the investigators considered such cultures unhelpful and unnecessary. This position was supported by a recent cost-effectiveness study (37) , in which it was estimated that the routine use of pretherapy cultures in lower urinary tract infection increases costs by 40%, but decreases the overall duration of symptoms by only 10%.
As recently reviewed (10), rapid tests for detecting urinary leukocytes, erythrocytes, and bacteria permit presumptive confirmation of urinary tract infection at the time of the pretherapy evaluation without the expense and delays associated with urine culture. When pyuria in voided urine specimens is carefully assessed using the hemocytometer method, and when urinary tract infection is defined as more than 10^ cfu/mL plus acute urinary symptoms, pyuria is a highly sensitive indicator of urinary tract infection (10). Its absence should cause the clinician to question the diagnosis of urinary tract infection. The leukocyte esterase "dipstick" method is somewhat less sensitive in identifying pyuria than the hemocytometer method (38) , but it can serve as an alternative approach where microscopy is not available.
Microscopic hematuria is found in 40% to 60% of cases of acute cystitis (10, 37, 39) and is uncommon in other dysuric syndromes. Thus, it is a highly specific indicator of cystitis in women with dysuria. Microscopic bacteriuria, which is most conveniently assessed using gram-stained, uncentrifuged urine, is found in over 90% of urinary tract infections with colony counts of 105 cfu/mL or more, and is a highly specific finding (31, 40). However, bacteria are not readily detected microscopically with lower colony-count infections (102 to 10^ cfu/mL). Thus, microscopic hematuria and bacteriuria lack sensitivity but are highly specific for urinary tract infection. Their absence in a patient whose symptoms are consistent with urinary tract infection should not be interpreted as evidence against the diagnosis. In contrast, the presence of bacteriuria or hematuria in the acutely dysuric patient is firm evidence of bacterial urinary tract infection.
In our view, patients with symptoms and signs suggestive of acute cystitis and in whom no complicating factors are present (Table 1) should have a urinalysis done (or alternatively, a leukocyte esterase test, urine gram-stain, or rapid filtration-stain test) (10). If positive for pyuria, hematuria, or bacteriuria, or a combination, one of these tests provides sufficient documentation of urinary tract infection that a urine culture and susceptibility testing can be omitted. A urine culture should be obtained, however, for patients in whom symptoms and urine examination findings leave the diagnosis of cystitis in question. Pretherapy cultures and susceptibility testing are also essential in the management of patients with suspected upper-tract infections and those in whom complicating factors are present (Table 1) , because in these situations various pathogens may be present and antibiotic therapy is best tailored to the individual organism (41) .
New Antimicrobial Agents to Treat Urinary Tract Infection
The clinician is confronted with an ever-expanding array of antimicrobial agents, including those shown in Table 3 , that can be used to treat urinary tract infections. The increasing prevalence of antimicrobial resistance to agents traditionally used to treat urinary tract infections, now evident among even communityacquired pathogens, to say nothing of nosocomial pathogens or those involved in complicated urinary tract infections (Table 2) , has created a need for newer, more active agents for treatment of urinary tract infection. In addition, the requirement for parenteral administration and the toxicities associated with the aminoglycosides, which have long been the mainstay of therapy for serious gram-negative infections or those involving resistant organisms, make the availability of broad-spectrum agents with decreased toxicity or with oral formulations most welcome. Amoxicillin combined with the beta-lactamase inhibitor clavulanate is active against beta-lactamaseproducing E. coli, Klebsiella, Enterobacter, and Proteus strains, which are resistant to ampicillin or amoxicillin, and is well absorbed by the oral route. Its efficacy in uncomplicated urinary tract infections has exceeded that of amoxicillin alone (43) and, in some studies (43, 44) , has equaled that of trimethoprim-sulfamethoxazole. Gastrointestinal side effects have been frequently associated with the use of this agent, however, resulting both from the clavulanate component and the amoxiciHin (43, 45) . In addition, as with ampicillin or amoxicillin alone (46) , use of this agent selects for ampicillin-resistant organisms in the fecal flora and predisposes to reinfection with ampicillin-resistant strains (45) . These considerations and its high cost ($1.71/dose) argue against its routine use as a first-line agent for acute urinary tract infection. The drug is most useful in patients with recurrent infection in whom antimicrobial resistance and infection with species other than E. coli is anticipated.
The combination of clavulanate and ticarciliin is active against an even broader range of pathogens than is ticarciliin alone, including Staphylococcus aureus and many beta-lactamase-producing gram-negative bacilli, in addition to Bacteroides fragilis and other anaerobic bacteria (47) . Studies evaluating this agent in the treatment of complicated or serious urinary tract infections, however, have yielded varying results, including several reports of high failure rates (48, 49) . In one study (50) , use of this agent to treat 18 women with acute pyelonephritis resulted in 2 outright therapeutic failures and 8 relapsing infections. Further data are needed to demonstrate the eifectiveness of this combination regimen in treating serious urinary tract infections.
Another new beta-lactam beta-lactamase inhibitor combination agent for intravenous use is ampicillinsulbactam, which offers much the same spectrum of activity as the oral preparation amoxicillin-clavulanate. Side eifeets associated with its use include rash, diarrhea, and pain at intramuscular injection sites (51) . Amdinocillin, another new intravenous beta-lactam, has only weak activity against gram-positive organisms and is not active against Pseudomonas, but is active against most Enterobacteriaciae (52) . The role of these two agents in treatment of urinary tract infection has yet to be clearly defined, but they are probably best reserved for situations in which conventional agents are unsatisfactory.
Trimethoprim, when used alone, appears to be as effective as trimethoprim-sulfamethoxazole to treat cystitis and is associated with fewer side effects, presumably because of the absence of the sulfa component (53) (54) (55) . It h^ been suggested (56) that the suifa component contributes to efficacy in treating complicated urinary tract infections or renal infection but not acute cystitis.
Among the recently introduced intravenous antimicrobial agents are the extended-spectrum penicillin derivatives piperaeillin, mezlocillin, and azlocillin. These agents retain ampicillin's activity against Enterococcus and offer activity against many ampicillin-resistant gram-negative bacilli (57-60), making them potentially attractive agents for use in patients with nosocomial urinary tract infections. The prevalence of resistance to this class of agents, however, even among pathogens causing community-acquired pyelonephritis (Table  2) , is high enough that it would be inadvisable to use them empirically as monotherapy in this setting (60) . This recommendation is supported by the results of a study (61) in which the use of piperaeillin or carbeniciilin alone in treating 26 patients with acute pyelonephritis was associated with outright failure of therapy in I patient and with relapse or recurrence in an additional 7 patients.
The third-generation cephalosporins are more reliably active against community-acquired and nosocomial gram-negative pathogens than are most other standard beta-lactam antibiotics (Table 2) (62) . In contrast, therapy with ceftriaxone in a similar population yielded only 1 relapse among 23 patients treated (63) . The cost of these agents ( Table 3) should limit their use to situations where parenteral therapy is required and resistance to standard antibiotics is likely (64) .
Imipenem, combined with an inhibitor of its metabolism by renal tubular cells (cilastatin), has been used successfully to treat serious urinary tract infections (65) (66) (67) . Failure to respond and relapse after therapy, however, has also been reported (68, 69) . Imipenem should be reserved to treat resistant infections that cannot be managed with other agents.
Aztreonam is the only available agent in a novel class of antimicrobials-the monobactams. Its spectrum of activity is similar to that of the aminoglycosides; it has broad activity against all gram-negative bacilli (including Pseudomonas aeruginosa) but is not active against gram-positive or anaerobic organisms. Its advantages include minimal toxicity and the absence of cross-sensitivity to the agent among persons with immediate hypersensitivity reactions to other penicillin derivatives (70) . A single dose of aztreonam in the therapy of cystitis gave an 84% success rate (71) , and a multi-dose regimen cured 93% of patients with various forms of urinary tract infection even though due to multiply resistant pathogens (71) . Encouraging results have been reported with this agent in the treatment of complicated or hospital-associated urinary tract infections (72, 73) , even with as low a dose as 500 mg administered twice daily (73), although frequent relapses have heen described (74) . It also may prove to be useful in situations where standard agents are contraindicated.
Norfloxacin, the first of the new fluoroquinolone antibiotics to be marketed in the United States, is active against all of the usual urinary tract pathogens, including Pseudomonas aeruginosa, and is currently available only in an oral preparation. It has proved to be as effective as trimethoprim-sulfamethoxazole in uncomplicated cystitis and may have fewer associated adverse effects (75, 76) . However, these studies used longer courses of therapy than were necessary, which probably exaggerated the toxicities of trimethoprimsulfamethoxazole. The high comparative cost of norfioxacin ($1.92/dose) probably limits its role in the treatment of uncomplicated urinary tract infection to selected patients with intolerance to other agents or a known resistant pathogen. In contrast, in a treatment trial for nosocomial urinary tract infections (77), oral norfioxacin was as effective as conventional parenteral therapy, and was less toxic and dramatically less expensive, suggesting that norfioxacin may offer significant advantages in this clinical settingCiprofloxacin is a fiuoroquinolone antibiotic with much the same spectrum as norfioxacin but with enhanced activity against Pseudomonas aeruginosa. In the treatment of uncomplicated cystitis, oral ciprofloxacin was as effective as trimethoprim-sulfamethoxazole and was associated with fewer adverse efFects, although the duration of therapy selected (10 days) may have exaggerated the side efFects of trimethoprimsulfamethoxazole (78) . Many studies (79) (80) (81) (82) (83) (84) (85) (86) have assessed the efficacy of oral ciprofloxacin in the treatment of complicated urinary tract infections, particularly those involving Pseudomonas or other multiresistant gram-negative organisms. In general, the response has been comparable or superior to that expected with the use of traditional agents in similar patients. Relapses were noted in 5% to 30% of patients in these studies, with disturbing increases in the minimum inhibitory concentration of ciprofioxacin for the posttherapy isolates in several cases (80, 83) . Intravenous ciprofloxacin has performed well in the treatment of serious and complicated urinary tract infections (87, 88) , but is not yet marketed in the United States. This agent ofFers great promise for the oral or intravenous therapy of serious or comphcated urinary tract infections, particularly with Pseudomonas or other resistant pathogens. Because oral ciprofloxacin oflers the advantages of greater tissue levels and increased activity against Pseudomonas compared with norfloxacin, it would be the preferred agent for treating invasive or pseudomonal urinary tract infections and would be the best choice for formularies if a single fluoroquinolone was desired. Larger series and comparative trials will be needed to better define the role of the intravenous preparation of ciprofloxacin in urinary tract infection therapy.
Individualized Therapy for Urinary Tract Infection Syndromes

Acute Cystitis
With many effective agents from which to choose, a major focus of recent urinary tract infection research has been duration of therapy. The traditional approach to treating lower urinary tract infection was 7 to 14 days of therapy with an oral antibiotic (89) . However, acute cystitis is a superficial infection and in many patients can be readily eradicated by a single dose of oral or intramuscular antibiotic (21), or even by a single episode of bladder lavage with an antibiotic solution (11, 21). As recently reviewed in detail (90) (91) (92) , single-dose therapy is effective in treating most women with acute cystitis, and is less expensive and associated with significantly fewer side effects than traditional therapy. Considerations that have prevented widespread adoption of single-dose therapy are its somewhat lower efficacy in controlled trials with adequate sample size (36, (92) (93) (94) , and concerns regarding its use in high-risk patients such as pregnant women, patients with diabetes or immunosuppressive conditions, and patients with urinary tract abnormalities or occult upper-tract infection, all of whom may be more likely to fail single-dose therapy and to develop severe complications if the infection is not eradicated (27, 92, 95) .
With regard to the adequacy of single-dose therapy for occult upper-tract infection, several studies (15, 18, 96, 97) have shown that patients with occult renal infection are more likely to experience relapse after single-dose therapy than patients with infection limited to the bladder, and that among such patients these relapsing infections may be difficult to eradicate even with repeated conventional courses of antimicrobial therapy. Other studies (36, 94) have failed to confirm these findings.
In attempting to reconcile these apparently confiicting results, it is necessary to consider not only the site of infection and the duration of therapy, but also the antimicrobial agent used. In studies evaluating therapy for presumed cystitis in which the outcome was correlated with the site of infection (as determined by antibody-coated bacteria testing), apparent relapse among patients with occult renal infection was encountered after treatment with trimethoprim or trimethoprim-sulfamethoxazole in only 6 of 37 patients given single-dose therapy, and in only I of 86 given at least 10 days of therapy (Table 4) . Consistent trends were reported in 7 of the 8 contributing studies (23, 36, 55, 94, 98, 99) (Stamm WE. Unpublished data.), with the remaining study contributing a single patient only (100) . These data would suggest that single-dose therapy with trimethoprim or trimethoprim-sulfamethoxazole effectively eradicates most occult renal infections, but that 10-day therapy might be even more effective.
In contrast, apparent relapse occurred after treatment with ampicillin, amoxicillin, cyciacillin, or an oral cephalosporin in approximately 45% of patients with occult renal infection regardless of whether single-dose therapy or a longer course of therapy was used (Table 4) . With these agents, relapse occurred in only 16% of patients who had antibody-coated bacteria-negative infections. Consistent trends were seen in seven of the eight contributing studies (15, 16, 19, 96, 97, 99, 101) , with the higher success rate with ampicillin for antibody-coated bacteria-positive infections noted by Stamm and colleagues (23) (ten of ten relapse-free after 14-day or 42-day therapy with ampicillin), possibly attributable to the longer mean duration of therapy, exclusion of patients with resistant organisms, and relatively small sample size (Stamm WE. Unpublished data.)
Higher cure rates were thus observed with trimethoprim and trimethoprim-sulfamethoxazole, compared with ampicillin and related agents, regardless of the site of infection or the duration of therapy. Single-dose therapy with ampicillin and related oral beta-lactam agents was much less successful in antibody-coated bacteria-positive than in antibody-coated bacteria-negative infections, but longer courses of therapy with these oral beta-lactam agents in antibody-coated bacteria-positive infections were little more effective than was single-dose therapy.
The high incidence of resistance to ampicillin among pathogens from community-acquired urinary tract infections (Table 2) probably contributes substantially to the decreased efficacy of ampicillin and + Minimum estimate of number in relapse-free group. J AMP = ampiciilin; AMX = amoxicillin; CCL = cyclacillin; CEX = ccphalexin; CEF ^ cefaclor. § Combined groups of single dose plus > 10 days. II Trimethoprim (TMP) or trimethoprim-sulfamethoxazoie (TMX).
amoxiciilin in antibody-coated bacteria-positive infections. In two studies (16, 97) in which the outcome of therapy was correlated with the results of both atitibody-coated bacteria tests and antimicrobial-susceptibility tests, the Hkelihood of relapse was greatest (65%) after therapy with amoxicillin for an antibodycoated bacteria-positive urinary tract infection when due to an ampicillin-resistant organism (Table 5 ). However, even among patients with ampicillin-susceptible pathogens, antibody-coated bacteria-positive infections did not respond as well to therapy with ampicillin or amoxicillin (whether as single-dose or 14-day therapy) as did antibody-coated bacteria-negative infections. Adverse pharmacokinetic properties may also contribute to the comparative inefficacy of ampicillin and related agents in the treatment of antibody-coated bacteria-positive infections in that the oral beta-lactams are eliminated much more rapidly than trimethoprimsulfamethoxazole (99) . In addition, trimetboprim is concentrated in renal tissues to a greater extent than is ampicillin (55, 102) .
Recent studies by Fihn and colleagues (94; Stamm WE, unpublished data) suggest that an additional problem in evaluating the relation of relapse to length of therapy, antibody-coated bacteria positivity, and antimicrobial agent used may be the definition of relapse. In general, re-isolation of the original infecting organism after treatment (especially in an antibodycoated bacteria-positive patient) has been thought to represent persistent renal infection. However, Fihn and colleagues (94) showed that single-dose trimethoprim-sulfamethoxazole failed to eradicate vaginal introital E. coli as effectively as did 10-day therapy (Stamm WE. Unpublished data.) Because most "relapses" in this study were in fact early post-therapy recurrences in antibody-coated bacteria-negative patients, these "relapses" were more likely caused by reintroduction of the original infecting strain that had persisted in the vaginal introitus after therapy. Thus, some (and perhaps most) "relapses" after single-dose therapy may represent failure of single-dose therapy to eliminate E. coli from the vaginal reservoir, followed by ascending re-infection, rather than true persistent renal infection. This hypothesis would explain the higher apparent relapse rates noted after therapy with ampicillin or amoxicillin, both of which are known to have a poor ability to alter carriage of E. coli in the vaginal reservoir (45, 46) .
The use of a 3-day course of therapy with amoxicillin, trimethoprim, trimethoprim-sulfamethoxazole, or doxycycline has been associated with an incidence of adverse effects as low as that seen with single-dose therapy and with cure rates that appear comparable to those achieved with longer courses of therapy (103) (104) (105) . In theory, 3-day therapy can be expected to be more effective than single-dose therapy in patients with unrecognized compHcating factors. Thus, although further studies are needed, 3-day therapy may be the preferred short-course regimen to treat acute uncomplicated lower urinary tract infection. Shortcourse therapy (Tables 6 and 7) should be reserved for patients with presumed acute cystitis who have no known complicating factors (Table 1) . When any of these complicating factors are present in a patient with presumed acute lower urinary tract infection, therapy should be continued for at least 7 days.
Acute Pyelonephritis
Patients with acute pyelonephritis can be subdivided into three groups: those with mild acute pyelonephritis which can be managed in the outpatient setting; those with uncomplicated acute pyelonephritis who are sufficiently ill to require hospitaiization for parenteral therapy; and those with complicated infection occurring in the setting of previous catheterization, hospitaiization, urologic surgery, or known urologic abnormalities (27). The first group, who represent a few patients with acute pyelonephritis, can be treated successfully as outpatients with oral antibiotics as long as adequate compliance and follow-up can be assured (6, 23, 106) ( Table 8) . A recent cost analysis showed that outpatient therapy for acute pyelonephritis was considerably less expensive than inpatient therapy (106) . Therapy for the second group, most patients with acute pyelonephritis, requires hospitaiization, intravenous fluids, and parentera! antibiotics (Table 9 ) because of the patient's extreme debility and inability to take oral nourishment or medications (6).
The combination of ampicillin and an aminoglycoside has traditionally been recommended as empiric therapy for patients hospitalized with uncomplicated acute pyelonephritis, with ampicillin being continued alone if the infecting organism proves susceptible (6). However, because of the increasing frequency of resistance to ampicillin among even community-acquired E. coli strains (Table 2) , the attractiveness of ampicillin as part of an empiric regimen for gram-negative infections has greatly diminished. A major advantage of the traditional ampiciilin-gentamicin regimen is its effectiveness against both Enterococcus and Pseudomonas in addition to other gram-negative bacilli. In uncomplicated acute pyelonephritis due to gramnegative bacilli, however, such coverage is unnecessary.
Given the availability of a number of altemative intravenous antibiotics with activity against most Enterobacteriaciae, and the capability of excluding enterococcal infection with the urine gram-stain, it may be preferable to initiate therapy for unequivocal uncomplicated acute pyelonephritis due to gram-negative bacilli with a single intravenous agent such as trimethoprim-sulfamethoxazole, a third-generation cephalosporin (63) , or an aminoglycoside alone (62, 63) while awaiting culture results. The selection of which of these drugs to use depends on cost considerations and on local sensitivity patterns. As shown in Table 2 , in our geographic area any of these three agents used alone would provide adequate coverage. Therapy can be modified after 24 to 48 hours when susceptibility testing results are available. We recommend the use of parenteral therapy until the patient is able to take fiuids by mouth and is symptomatically improved and afebrile. The duration of therapy for acute pyelonephritis in women need not be longer than 14 days initially (107; Stamm WE, unpublished data.) In a recent study (23), side effects and re-infections with antimicrobial resistant organisms were commoner in women with mild upper urinary tract infection treated with ampicillin or trimethoprim-sulfamethoxazole for 6 weeks, compared with those given 14-day therapy. For the few patients with pyelonephritis who have relapse of infection after 14-day therapy, retreatment for 6 weeks is usually curative (108) . Shorter courses of therapy cure some patients with acute pyelonephritis, as reflected in reports of success (109, 110) with as few as 5 days of therapy. In a recent controlled trial (111), however, 1 week of therapy using the combination of • Susceptibility of pathogen to selected antibiotics should be confirmed with in-vitro susceptibility testing in patients with complicating factors.
t Twice-daily dosing can probably be used for all medications listed when there are no complicating factors.
X Patients without complicating factors can be treated for 3 days. In the presence of complicating factors, therapy should be continued for 7 days.
§ Costs are based on manufacturers' average wholesale price (reference 42).
II Preferred antimicrobial agents.
pivampicillin and pivmecillinam resulted in significantly more bacteriologic recurrences compared with 3 weeks of therapy. Thus, the routine use of less than 14-day therapy is not supported by currently available comparative clinical trials (107) . As in lower urinary tract infection, the presence of complicating factors in patients with upper urinary tract infection argues for more aggressive management, closer follow-up, and possibly a longer duration of therapy. Reference to recent urine culture reports or to the gram-stain of the acute urine specimen may be used to broaden, but should not be relied on to narrow, the initial spectrum of antimicrobial coverage. Urologic consultation should be considered as part of the initial management of such patients. Similarly, patients with suspected pyelonephritis who have symptoms of renal colic or a stone on their admission abdominal roentgenogram, or who fail to improve after 3 days of appropriate antibiotic therapy, should be suspected of harboring a stone, an underlying anatomic abnormality, urinary tract obstruction, or an acquired complication of infection, such as an intrarenal abscess. In such cases, ultrasonography, computed tomography, or an excretory urogram should be done and urologic consultation obtained if indicated (5, 25, 26).
Post-Therapy Urine Cultures
Urine cultures after therapy have traditionally been recommended to confirm successful eradication of infection in women with acute urinary tract infection. Whether they are truly helpful in patients with uncomplicated lower tract infection is questionable. Although concern has been expressed (91) that close follow-up is needed to detect recurrent bacteriuria after short-course therapy for acute cystitis because of the possibility of inadequately treated occult renal infection, it is important to recognize that relapse occurs infrequently even in the antibody-coated bacteria-positive population when trimethoprim-sulfamethoxazole is used instead of ampicillin (Table 4) . Further, the incidence of symptomatic urinary tract infection after therapy for acute cystitis is not reduced when routine foUow-up cultures are used compared with when cultures are done only in symptomatic patients (36, 112) . In addition, the large number of post-therapy cultures required to identify a single case of asymptomatic bacteriuria may result in a cost of over $2000/case detected (36) , and the benefit of detecting and treating asymptomatic bacteriuria in nonpregnant women has never been demonstrated (113, 114) . For most cases of acute uncomplicated cystitis, therefore, test-of-cure cultures are probably unwarranted if symptoms have resolved completely.
Post-therapy cultures should be obtained, however, in patients with persisting symptoms and in those with known complicating factors ( Table 1 ). In patients with acute pyelonephritis, post-treatment cultures should be obtained at least once, preferably about 2 weeks after therapy (41) .
Conclusions
In uncomplicated acute lower urinary tract infection empiric short-course therapy (single-dose or 3-day therapy) with one of several antibiotics (Tables 6 and  7) is preferred if there are no complicating factors. When complicating factors are present (Table 1) , it is advisable to determine the antibiotic-susceptibility profile of the infecting organism and to continue therapy with an appropriate agent for at least 7 days. Ampicillin and related drugs are probably inferior to trimethoprim-sulfamethoxazole to treat occult renal • Oral therapy should be reserved for patients with pyelonephritis who lack complicating factors and who are able lo take medications, food, and fluids by mouth. (See text for discussion of mild compared with severe pyelonephritis.) t Susceptibility of pathogen to selected antimicrobial agent should be conllrmed with in-vitro susceptibility testing. Initial therapy must be chosen to provide activity against all likely pathogens (see text).
t Therapy should be continued for 14 days. § Costs are based on manufacturers' average wholesale price (reference 42).
II Preferred antimicrobial agents. * Therapy is given intravenously until symptoms have improved and the patient is afebrile and able to take oral medication. Oral therapy is then continued to complete a 14-day course (combined intravenous and oral).
t Susceptibility of pathogen to selected antimicrobial agent should be confirmed with in-vitro susceptibility testing. Initial therapy must provide activity against all hkely pathogens.
t Costs are based on manufacturers' average wholesale price (reference 42).
§ Preferred antimicrobial agents. II Cost is based on a 70-kg patient. 11 In more severely ill patients, higher doses may be preferable.
infection, most cases of which can be cured with a single dose of trimethoprim-sulfamethoxazole. In acute pyelonephritis, most patients require hospitalization and treatment with intravenous antibiotics until they can take oral medications. In uncomplicated cases, a single broad-spectrum intravenous agent can be used initially (Table 9) , followed by an oral agent selected on the basis of antibiotic-susceptibility testing results. Patients with uncomplicated acute pyelonephritis who are not as ill can be managed with oral therapy as outpatients, again with reference to the results of antibiotic-susceptibility testing (Table 8) .
Complicated acute pyelonephritis requires more aggressive diagnostic and therapeutic measures. Therapy for acute uncomplicated pyelonephritis should be given for 14 days. The role of post-therapy cultures in the management of urinary tract infection is not well defined; however, cultures probably can be safely omitted in most cases of uncomplicated acute cystitis.
